Wuhan General Group Inc
| OTC: WUHN | Healthcare / Drug Manufacturers / USA |
| 0.0229 | 0 | 0.00 | Vol 6.00K | 1Y Perf -92.23% |
| Mar 22nd, 2023 12:26 |
| BID | 0.0000 | ASK | 0.0000 | ||
| Open | 0.0229 | Previous Close | 0.0229 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.25 | Earnings Rating | — | |
| Market Cap | 777.75K | Earnings Date | - | |
| Alpha | 0.20 | Standard Deviation | 0.92 | |
| Beta | 2.67 |
Today's Price Range 0.02290.0229 | 52W Range 0.01150.5195 | 5 Year PE Ratio Range -0.300053.000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -15.09% | ||
| 1 Month | -5.42% | ||
| 3 Months | 38.94% | ||
| 6 Months | -23.58% | ||
| 1 Year | -92.23% | ||
| 3 Years | -18.13% | ||
| 5 Years | -95.04% | ||
| 10 Years | 0.00% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2.30 | |||
ROE last 12 Months | -9.97 | |||
ROA (5Y Avg) | -0.79 | |||
ROA last 12 Months | -3.95 | |||
ROC (5Y Avg) | -1.81 | |||
ROC last 12 Months | -1.81 | |||
Return on invested Capital Q | -2.20 | |||
Return on invested Capital Y | -1.81 | |||
Assets Turnover | - | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.70 | ||||
| 0.04 | ||||
| - | ||||
| 0.20 | ||||
| - | ||||
| -0.64 | ||||
| 0.14 | ||||
| 3.16 | ||||
| 3.05M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.60 | ||||
| 1.10 | ||||
| - | ||||
| 1.11 | ||||
| 0.10 | ||||
| Leverage Ratio | - |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.10 | ||||
| 0.70 | ||||
| 4.00 | ||||
| -12.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| -2.91 | ||||
| 0.73 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2012 | - | -0.10 | - |
| Q03 2011 | - | -0.07 | - |
| Q02 2011 | - | 0.06 | - |
| Q03 2010 | - | 0.10 | - |
| Q02 2010 | - | 0.04 | - |
| Q01 2010 | - | 0.05 | - |
| Q04 2009 | - | 0.11 | - |
| Q03 2009 | - | 0.08 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 6.00K |
| Shares Outstanding | 33.93K |
| Shares Float | 14.08M |
| Trades Count | 1 |
| Dollar Volume | 138 |
| Avg. Volume | 0 |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 0 |
Wuhan General Group Inc
Wuhan General Group (China) Inc is an alternative medicinal and botanicals company focused on the application of emerging technologies as well as the clinical research and health application of cannabidiol (CBD)-based medicine to the human and pet care industry for cancer, cardiovascular, mental disorders, chronic pain, and others in Canada, the United States, Europe, and Australia. It supplies medical grade CBD products, and superior patient care.
CEO: Ruilong Qi
Telephone: +1 514 928-7368
Address: 6500 Trans-Canada Highway, Montreal H9R 0A5, QC, CAN
Number of employees: 700
